Ramit Mahajan

Ramit Mahajan

Auto-generated profile, based on publicly available information

Ramit Mahajan

Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2019 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
ASAjit Sood
Ajit Sood
RMRamit Mahajan
Ramit Mahajan
ASArshdeep Singh
Arshdeep Singh
VMVandana Midha
Vandana Midha
VMVarun Mehta
Varun Mehta
APAnmol Singh Pannu
Anmol Singh Pannu
Objectives: To study the role of faecal microbiota transplantation [FMT] in maintenance of remission in ulcerative colitis [UC].Methods: In this pilot study, patients with UC in clinical remission achieved after multi-session FMT were randomly allocated to either maintenance FMT or placebo colonoscopic infusion every 8 weeks, for 48 weeks. The standard of care [SOC] therapy was continued in all patients. The primary endpoint was maintenance of steroid-free clinical remission [Mayo score ≤2, all subscores ≤1] at Week 48. Secondary endpoints were achievement of endoscopic remission [endoscopic Mayo score 0] and histological remission [Nancy grade 0, 1] at Week 48.Results: In all, 61 patients in clinical remission were randomised to receive either FMT [n = 31] or placebo [n = 30]. The primary outcome was achieved in 27/31 [87.1%] patients allocated FMT versus 20/30 [66.7%] patients assigned placebo [p = 0.111]. Secondary endpoints of endoscopic remission (FMT: 18/31 [58.1%] versus placebo: 8/30 [26.7%], p = 0.026) and histological remission (FMT: 14/31 [45.2%] versus placebo: 5/30 [16.7%], p = 0. 033) were achieved in a significantly higher number of patients with FMT. Three patients receiving FMT [9.7%] and 8 patients on placebo [26.7%] relapsed. There were no serious adverse events necessitating discontinuation in patients on FMT; one patient who relapsed on placebo required colectomy.Conclusions: Maintenance FMT in patients who are in clinical remission may help sustain clinical, endoscopic and histological remission in patients with UC.

22 December 2023 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
ASArshdeep Singh
Arshdeep Singh
MGManjeet Kumar Goyal
Manjeet Kumar Goyal
VMVandana Midha
Vandana Midha
RMRamit Mahajan
Ramit Mahajan
KKKirandeep Kaur
Kirandeep Kaur
ASAjit Sood
Ajit Sood
INTRODUCTION: Intravenous corticosteroids are the mainstay of treatment of patients hospitalized with acute severe ulcerative colitis (ASUC). However, 30%–40% of the patients are refractory to corticosteroids. We investigated whether addition of tofacitinib to corticosteroids improved the treatment responsiveness in patients with ASUC. METHODS: This single-center, double-blind, placebo-controlled trial randomized adult patients with ASUC (defined by the Truelove Witts severity criteria) to receive either tofacitinib (10 mg thrice daily) or a matching placebo for 7 days while continuing intravenous corticosteroids (hydrocortisone 100 mg every 6 hours). The primary end point was response to treatment (decline in the Lichtiger index by >3 points and an absolute score <10 for 2 consecutive days without the need for rescue therapy) by day 7. The key secondary outcome was the cumulative probability of requiring initiation of infliximab or undergoing colectomy within 90 days following randomization. All analyses were performed in the intention-to-treat population. RESULTS: A total of 104 patients were randomly assigned to a treatment group (53 to tofacitinib and 51 to placebo). At day 7, response to treatment was achieved in 44/53 (83.01%) patients receiving tofacitinib vs 30/51 (58.82%) patients receiving placebo (odds ratio 3.42, 95% confidence interval 1.37–8.48, P = 0.007). The need for rescue therapy by day 7 was lower in the tofacitinib arm (odds ratio 0.27, 95% confidence interval 0.09–0.78, P = 0.01). The cumulative probability of need for rescue therapy at day 90 was 0.13 in patients who received tofacitinib vs 0.38 in patients receiving placebo (log-rank P = 0.003). Most of the treatment-related adverse effects were mild. One patient, receiving tofacitinib, developed dural venous sinus thrombosis. DISCUSSION: In patients with ASUC, combination of tofacitinib and corticosteroids improved treatment responsiveness and decreased the need for rescue therapy.

30 January 2022 in Intestinal Research
Verified
Journal Article
Open access
PDF file
ASArshdeep Singh
Arshdeep Singh
RMRamit Mahajan
Ramit Mahajan
SKSaurabh Kedia
Saurabh Kedia
ADAmit Kumar Dutta
Amit Kumar Dutta
AAAbhinav Anand
Abhinav Anand
ASAjit Sood
Ajit Sood
Inflammatory bowel disease (IBD), once considered a disease of the Western hemisphere, has emerged as a global disease. As the disease prevalence is on a steady rise, management of IBD has come under the spotlight. 5-Aminosalicylates, corticosteroids, immunosuppressive agents and biologics are the backbone of treatment of IBD. With the advent of biologics and small molecules, the need for surgery and hospitalization has decreased. However, economic viability and acceptability is an important determinant of local prescription patterns. Nearly one-third of the patients in West receive biologics as the first/initial therapy. The scenario is different in developing countries where biologics are used only in a small proportion of patients with IBD. Increased risk of reactivation of tuberculosis and high cost of the therapy are limitations to their use. Thiopurines hence become critical for optimal management of patients with IBD in these regions. However, approximately one-third of patients are intolerant or develop adverse effects with their use. This has led to suboptimal use of thiopurines in clinical practice. This review article discusses the clinical aspects of thiopurine use in patients with IBD with the aim of optimizing their use to full therapeutic potential.

3 October 2023 in Indian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
KDKhushdeep Dharni
Khushdeep Dharni
ASArshdeep Singh
Arshdeep Singh
SSSonika Sharma
Sonika Sharma
VMVandana Midha
Vandana Midha
KKKirandeep Kaur
Kirandeep Kaur
ASAjit Sood
Ajit Sood

30 April 2021 in Intestinal Research
Verified
Journal Article
Open access
PDF file
ASAjit Sood
Ajit Sood
KKKirandeep Kaur
Kirandeep Kaur
RMRamit Mahajan
Ramit Mahajan
VMVandana Midha
Vandana Midha
ASArshdeep Singh
Arshdeep Singh
NRN. Sridhara Rao
N. Sridhara Rao
Background/Aims: The national registry for inflammatory bowel disease (IBD) was designed to study epidemiology and prescribing pattern of treatment of IBD in India. Methods: A multicenter, cross-sectional, prospective registry was established across four geographical zones of India. Adult patients with ulcerative colitis (UC) or Crohn’s disease (CD) were enrolled between January 2014 and December 2015. Information related to demographics; disease features; complications; and treatment history were collected and analyzed. Results: A total of 3,863 patients (mean age, 36.7 ± 13.6 years; 3,232 UC [83.7%] and 631 CD [16.3%]) were enrolled. The majority of patients with UC (n = 1,870, 57.9%) were from north, CD was more common in south (n = 348, 55.5%). The UC:CD ratio was 5.1:1. There was a male predominance (male:female = 1.6:1). The commonest presentation of UC was moderately severe (n = 1,939, 60%) and E2 disease (n = 1,895, 58.6%). Patients with CD most commonly presented with ileocolonic (n = 229, 36.3%) inflammatory (n = 504, 79.9%) disease. Extraintestinal manifestations were recorded among 13% and 20% of patients in UC and CD respectively. Less than 1% patients from both cohorts developed colon cancer (n = 26, 0.7%). The commonly used drugs were 5-aminosalicylates (99%) in both UC and CD followed by azathioprine (34.4%). Biologics were used in only 1.5% of patients; more commonly for UC in north and CD in south. Conclusions: The national IBD registry brings out diversities in the 4 geographical zones of India. This will help in aiding research on IBD and improving quality of patient care.

13 August 2019 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
ASAjit Sood
Ajit Sood
ASArshdeep Singh
Arshdeep Singh
RMRamit Mahajan
Ramit Mahajan
VMVandana Midha
Vandana Midha
VMVarun Mehta
Varun Mehta
KKKirandeep Kaur
Kirandeep Kaur